• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis, Inc. - Common Stock (NQ:EXEL)

    43.95 -0.32 (-0.72%)
    Streaming Delayed Price Updated: 1:02 PM EST, Jan 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 873,567
    Open 44.47
    Bid (Size) 43.93 (100)
    Ask (Size) 43.97 (900)
    Prev. Close 44.27
    Today's Range 43.72 - 44.98
    52wk Range 32.30 - 49.62
    Shares Outstanding 315,048,788
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
    Via Chartmill
    Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
    Via Chartmill

    Performance

    YTD
    +0.8%
    +0.8%
    1 Month
    -5.0%
    -5.0%
    3 Month
    +9.9%
    +9.9%
    6 Month
    -1.0%
    -1.0%
    1 Year
    +34.3%
    +34.3%

    More News

    Read More
    EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
    Via Chartmill
    News headline image
    Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    2 Healthcare Stocks to Buy for 2026 and Beyond ↗
    Via The Motley Fool
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Preview: Exelixis's Earnings ↗
    Via Benzinga
    News headline image
    Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
    Via Chartmill
    News headline image
    Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
    Via Chartmill
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
    Via The Motley Fool
    News headline image
    EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
    Via Chartmill
    News headline image
    Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
    Via Chartmill
    News headline image
    S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
    Via MarketMinute
    Topics Economy Regulatory Compliance Stocks
    News headline image
    Global Markets Rally on Hopes for US Government Shutdown Resolution
    Via MarketMinute
    Topics Bonds Economy Government
    News headline image
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    News headline image
    What's Driving the Market Sentiment Around Exelixis Inc? ↗
    Via Benzinga
    News headline image
    Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
    Via Benzinga

    Frequently Asked Questions

    Is Exelixis, Inc. - Common Stock publicly traded?
    Yes, Exelixis, Inc. - Common Stock is publicly traded.
    What exchange does Exelixis, Inc. - Common Stock trade on?
    Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Exelixis, Inc. - Common Stock?
    The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
    What is the current price of Exelixis, Inc. - Common Stock?
    The current price of Exelixis, Inc. - Common Stock is 43.95
    When was Exelixis, Inc. - Common Stock last traded?
    The last trade of Exelixis, Inc. - Common Stock was at 01/26/26 01:02 PM ET
    What is the market capitalization of Exelixis, Inc. - Common Stock?
    The market capitalization of Exelixis, Inc. - Common Stock is 13.85B
    How many shares of Exelixis, Inc. - Common Stock are outstanding?
    Exelixis, Inc. - Common Stock has 14B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.